A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

For trade group the Pharmaceutical Research and Manufacturers of America (PhRMA), the fight against pricing provisions in the ...

Forbes recently listed the best employers in the U.S. and in each state for 2024, with 15 Delaware employers included. Find out how they fared.

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.

Nevada U.S. Senator Jacky Rosen, Colleagues File Amicus Brief Urging Court to Uphold Medicare’s Ability to Negotiate Lower ...

Biohaven's drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

Intel jumps on reports of Apollo investment and Qualcomm takeover interest, Palantir and Dell join the S&P 500, and TSMC and Samsung reportedly mulling UAE chip megafactories. Here's what investors ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

Cerulean Ventures, a climate tech venture capital firm in Santa Barbara, Calif,, closed a $10 million pre-seed fund to work ...

AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...